Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.42Infinium Pharmachem Ltd demonstrates a mixed financial performance. The company excels in solvency and profitability, indicating a strong ability to meet long-term obligations and generate profits. Growth prospects are also promising, driven by robust revenue and asset expansion. However, liquidity faces challenges due to negative operating cash flow, and efficiency is hampered by inventory and capital turnover issues. Financial metrics like earnings per share and book value per share raise concerns. While coverage of interest expenses is adequate, the absence of dividend coverage is notable. The company's strengths in profitability and solvency are partially offset by weaknesses in liquidity and efficiency, requiring attention to optimize working capital and improve operational performance. Overall, the company exhibits a blend of financial strengths and areas needing improvement for sustained growth and stability.
Health Score : 6.42Infinium Pharmachem Ltd demonstrates a mixed financial performance. The company excels in solvency and profitability, indicating a strong ability to meet long-term obligations and generate profits. Growth prospects are also promising, driven by robust revenue and asset expansion. However, liquidity faces challenges due to negative operating cash flow, and efficiency is hampered by inventory and capital turnover issues. Financial metrics like earnings per share and book value per share raise concerns. While coverage of interest expenses is adequate, the absence of dividend coverage is notable. The company's strengths in profitability and solvency are partially offset by weaknesses in liquidity and efficiency, requiring attention to optimize working capital and improve operational performance. Overall, the company exhibits a blend of financial strengths and areas needing improvement for sustained growth and stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
41.21
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
33.97
P/B RATIO
3.41
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
2.40
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.94
EV/EBITDA RATIO
17.75
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹265 as on Sep 1, 2026.
Growth Score : 8.00The growth ratios reveal a strong expansion in revenue and assets, but challenges in earnings per share and net income growth. The robust revenue growth rate and asset growth rate indicate successful market penetration and investment in new opportunities. However, the decline in earnings per share and net income growth needs attention to ensure profitability keeps pace with revenue. While the company is expanding, sustainable profitability must be a key focus.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 39.44 | 15.15 | 19.3 | 14.71 | 21.79 |
| Operating Profit Growth Rate | 100 | 60 | 18.75 | 0 | 15.79 |
| Earnings Per Share (EPS) Growth | 124.63 | -69.56 | -12.69 | -35.59 | 49.14 |
| Asset Growth Rate | 73.53 | 20.34 | 19.72 | 132.94 | -11.62 |
| Net Income Growth Rate | 133.33 | 42.86 | 20 | -33.33 | 75 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 2 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 3 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 4 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 5 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 6 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 60.35 | Neutral | 7.00 | 1.40 | 4.00 |
| 7 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 8 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 9 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 11 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
| 12 | PANCHSHEEL | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Infinium Pharmachem Ltd is an ISO 9001:2015 certified Indian specialty chemical manufacturer. The company focuses on producing Pharma Intermediates, Fine Chemicals, and Specialty Chemicals, catering to pharmaceutical, agrochemical, and other industrial sectors globally. It aims to be a reliable provider of quality chemical solutions.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Infinium Pharmachem Ltd's P/E ratio (TTM) is 41.21, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Infinium Pharmachem Ltd's P/B ratio is 3.41, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Infinium Pharmachem Ltd's P/S ratio is 2.40, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Infinium Pharmachem Ltd's PEG ratio is 0.94.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Infinium Pharmachem Ltd's EV/EBITDA ratio is 17.75.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Infinium Pharmachem Ltd's ROE is 11.57%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Infinium Pharmachem Ltd's ROA is 12.57%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Infinium Pharmachem Ltd's ROCE is 13%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Infinium Pharmachem Ltd's operating margin is 11.58%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Infinium Pharmachem Ltd's net margin is 7.37%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Infinium Pharmachem Ltd's current ratio is 2.11.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Infinium Pharmachem Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Infinium Pharmachem Ltd's interest coverage ratio is 7.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Infinium Pharmachem Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Infinium Pharmachem Ltd's EPS is 49.14.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹265. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2003
Headquarters: Mehsana, Gujarat
Core Offerings: Pharma Intermediates, Fine Chemicals, Specialty Chemicals, Custom Synthesis
Stock Listing: NSE (INFINIUM), BSE ({bse})
Promoter: Jignesh Shah / Infinium Pharmachem Ltd Promoter Group
Founded in 2003, Infinium Pharmachem Ltd began operations as a specialty chemical manufacturer focusing on pharma intermediates. The company secured ISO 9001:2015 certification. It steadily expanded its product portfolio and market reach, establishing itself in both domestic and international markets. A significant milestone was its successful IPO and listing on the NSE in March 2023, marking its transition to a publicly traded entity.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharma Intermediates | N/A | Operating Profit |
| Fine Chemicals | N/A | Operating Profit |
| Specialty Chemicals & Custom Synthesis | N/A | Operating Profit |
Pharma Intermediates: Manufactures key chemical compounds vital for the production of Active Pharmaceutical Ingredients (APIs), serving the generic and innovator pharmaceutical industries.
Fine Chemicals: Produces high-purity chemicals used in various specialized applications beyond pharmaceuticals, including agrochemicals and research & development.
Specialty Chemicals & Custom Synthesis: Offers bespoke chemical solutions and custom manufacturing services to meet specific client requirements, leveraging its R&D capabilities and manufacturing flexibility.
Jignesh Shah - Chairman & Managing Director. A chemical engineer with over two decades of experience, he is instrumental in the company's strategic growth and operational excellence. Kalpesh Shah - Joint Managing Director. A science graduate with extensive experience in the chemical industry, overseeing marketing and operational efficiencies.
No major subsidiaries reported.
Successful IPO and listing on NSE in March 2023. No major recent bonus/rights issues or significant M&A on record since then.
The Infinium Pharmachem Ltd share price today is ₹265 on NSE (INFINIUM), as of 26 Sept 2026.
As of 26 Sept 2026, Infinium Pharmachem Ltd share price is ₹265, with previous close ₹265. Today's range is ₹265 to ₹265. The 52-week range is ₹189.40 to ₹285.50.
As of today, Infinium Pharmachem Ltd's market cap is ₹455.8 crore (Small Cap).
Infinium Pharmachem Ltd's current P/E ratio is 41.21, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 31.50.
Infinium Pharmachem Ltd's current P/B ratio is 3.41.
Infinium Pharmachem Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Infinium Pharmachem Ltd's EPS (TTM) is ₹49.14.
Infinium Pharmachem Ltd is an ISO 9001:2015 certified Indian specialty chemical manufacturer. The company focuses on producing Pharma Intermediates, Fine Chemicals, and Specialty Chemicals, catering to pharmaceutical, agrochemical, and other industrial sectors globally. It aims to be a reliable provider of quality chemical solutions.
Infinium Pharmachem Ltd is promoted by Jignesh Shah / Infinium Pharmachem Ltd Promoter Group, holding 64.91% as of 26 Sept 2026.
Infinium Pharmachem Ltd is listed on NSE (INFINIUM) and BSE ({bse}). Its next quarterly results are expected on Q1 FY25 (July/August 2024).
